CTOs on the Move

AnaptysBio

www.anaptysbio.com

 
AnaptysBio is a privately-held antibody development company focused on novel programs in immuno-oncology and inflammation. The Company`s first-in-class proprietary pipeline includes ANB020, an anti-IL-33 antibody for the treatment of severe adult asthma and peanut allergy, and ANB019, an anti-IL-36 receptor antibody for the treatment of generalized pustular psoriasis. AnaptysBio`s SHM-XEL platform has pioneered the use of in vitro somatic hypermutation for antibody discovery and optimization, which replicates key features of the human immune system and overcomes limitations of prior antibody technologies. AnaptysBio has previously announced partnerships with several biopharmaceutical companies, including Novartis, Gilead, Celgene, Momenta and TESARO.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.anaptysbio.com
  • 10421 Pacific Center Court Suite 200
    San Diego, CA USA 92121
  • Phone: 858.362.6295

Executives

Name Title Contact Details

Funding

AnaptysBio raised $40M on 07/15/2015

Similar Companies

Meta Systems

Meta Systems is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Anthos Therapeutics

Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases. Anthos Therapeutics aims to combine the agility of a biotech with the rigor of a large pharmaceutical company. Anthos Therapeutics was launched by Blackstone Life Sciences in 2019.

Incellico Inc

Incellico Inc is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Culture Biosciences

Culture Biosciences develops automated bioreactor infrastructures and runs it as a service for biotech companies.

Gennao Bio

Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology.